Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Pipeline Review, H2 2018’, provides in depth analysis on Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology under development targeting Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

  • Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2)

- The report reviews Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics and enlists all their major and minor projects

- The report assesses Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aurigene Discovery Technologies Ltd

BeiGene Ltd

Bristol-Myers Squibb Co

Eli Lilly and Co

Elpiscience Biopharmaceuticals Co Ltd

F. Hoffmann-La Roche Ltd

GigaGen Inc

Incyte Corp ...

Aurigene Discovery Technologies Ltd

BeiGene Ltd

Bristol-Myers Squibb Co

Eli Lilly and Co

Elpiscience Biopharmaceuticals Co Ltd

F. Hoffmann-La Roche Ltd

GigaGen Inc

Incyte Corp

Interprotein Corp

Jounce Therapeutics Inc

Novartis AG

Symphogen A/S

TESARO Inc

Trellis Bioscience Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Overview

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Companies Involved in Therapeutics Development

Aurigene Discovery Technologies Ltd

BeiGene Ltd

Bristol-Myers Squibb Co

Eli Lilly and Co

Elpiscience Biopharmaceuticals Co Ltd

F. Hoffmann-La Roche Ltd

GigaGen Inc

Incyte Corp

Interprotein Corp

Jounce Therapeutics Inc

Novartis AG

Symphogen A/S

TESARO Inc

Trellis Bioscience Inc

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Drug Profiles

BGBA-425 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986258 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CA-170 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CA-327 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ES-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCAGN-2390 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3321367 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGB-453 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies 3 to Inhibit TIM3 for Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit TIM-3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit CD366 for Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-7121661 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit TIM-3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sym-023 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit TIM-3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRL-6061 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TSR-022 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Dormant Products

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Product Development Milestones

Featured News & Press Releases

Oct 01, 2018: TESARO announces data presentation on its melanoma drug candidate TSR-022 at the SITC 2018 Annual Meeting

Jul 10, 2018: Selexis provides update on antibody candidate Sym023

Apr 11, 2018: Agenus Presents preclinical data on INCAGN02390 at the American Association for Cancer Research (AACR) 2018 Annual Meeting

Nov 03, 2017: Curis to Present Data On Its Cancer Drug Candidate CA-170 at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit

Nov 03, 2017: Curis to Present Preclinical Data On Its Cancer Drug candidate CA-327 at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit

Sep 11, 2017: Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017

Aug 31, 2017: Curis Announces CA-170 Poster Presentation at ESMO 2017 Congress

May 25, 2017: Curis Announces Presentation on CA-170 at 2017 ASCO Annual Meeting

Nov 09, 2016: Curis Presents Early Clinical Pharmacokinetic and Biomarker Data from CA-170’s Phase 1 Trial at the SITC 2016 Conference

Oct 11, 2016: Curis Expands Oncology Pipeline with an Oral Small Molecule PD-L1/TIM-3 Immune Checkpoint Antagonist

Aug 08, 2016: Cancer Treatment Centers of America at Western Regional Medical Center is the first site in the world for new investigational anti-cancer treatment

Jun 04, 2016: TESARO Provides Update on TSR-022 at ASCO Investor Briefing

Jun 01, 2016: Curis Announces FDA Acceptance of Investigational New Drug Application for CA-170, the First Orally Available Small Molecule to Target and Inhibit Immune Checkpoints

Apr 25, 2016: Tesaro Announces Submission Of Investigational New Drug Application For ANTI-TIM-3 Antibody TSR-022 To The US FDA

Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CA-170 and PD-L1/TIM-3 Antagonist at AACR Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number ...

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Aurigene Discovery Technologies Ltd, H2 2018

Pipeline by BeiGene Ltd, H2 2018

Pipeline by Bristol-Myers Squibb Co, H2 2018

Pipeline by Eli Lilly and Co, H2 2018

Pipeline by Elpiscience Biopharmaceuticals Co Ltd, H2 2018

Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Pipeline by GigaGen Inc, H2 2018

Pipeline by Incyte Corp, H2 2018

Pipeline by Interprotein Corp, H2 2018

Pipeline by Jounce Therapeutics Inc, H2 2018

Pipeline by Novartis AG, H2 2018

Pipeline by Symphogen A/S, H2 2018

Pipeline by TESARO Inc, H2 2018

Pipeline by Trellis Bioscience Inc, H2 2018

Dormant Projects, H2 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018 ...

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports